sPinal coRd stimulatiOn coMpared With Lumbar InStrumEntation for Low Back Pain After Previous Lumbar Decompression (PROMISE): a Prospective Randomized Controlled Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 84
- 试验地点
- 2
- 主要终点
- Oswestry disability index / ODI
研究概览
简要总结
Low back pain affects people of all ages and has become the leading cause of living with disability worldwide. Patients, suffering from persistent pain after spinal surgery in the absence of any clear spinal pathology are defined of having a "failed back surgery syndrome (FBSS)" and treatment of FBSS remains a great controversy in the spinal community. Apart from conservative treatment, spinal fusion remains as therapeutic option. Furthermore, minimal invasive Neuromodulation techniques might be a promising alternative. Aim of this randomized interventional multi center study is to compare treatment success in FBSS patients with either spinal cord stimulation (SCS) or fusion surgery, 12 months after intervention according to the Oswestry Disability Index (ODI) and other scales and scores. Radiological and health economic outcome also will be analysed for thorough comparison of techniques. Additionally, the safety of the interventions needs to be compared.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years
- •Symptomatic degenerative disc disease with LBP as a predominant symptom for at least 6 months following pervious surgery for disc herniation
- •ODI score at least 21
- •Correctly signed informed consent form
排除标准
- •Spinal stenosis resulting in spinal claudication or neurological deficits
- •Spinal Instability (> 3 mm Motion on dynamic Lumbar X-rays)
- •Major psychiatric disorder
结局指标
主要结局
Oswestry disability index / ODI
时间窗: 12 months after intervention
A patient reported outcome measure to rate pain and disability
次要结局
- Pain medication(12 months after intervention)
- hospital length of stay(through study completion, an average of 2 years)
- Adverse events(12 months after intervention)
- SF36(12 months after intervention)
- EuroQOL 5D(12 months after intervention)
- Crossover rates(12 months after intervention)
